Advanced Life Sciences’ Cethromycin For CAP Cleared For FDA Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans third quarter NDA for mild-to-moderate community-acquired pneumonia indication.
You may also be interested in...
Wyeth’s Tygacil “Approvable” For CAP, Pushing Back FDA Action Until December
FDA seeks more analysis of data on patients with severe illness; Wyeth will submit a "complete response" by June 27.
Wyeth’s Tygacil “Approvable” For CAP, Pushing Back FDA Action Until December
FDA seeks more analysis of data on patients with severe illness; Wyeth will submit a "complete response" by June 27.
FDA Hearing To Consider Incentives For Antimicrobial Drug Development
Tax incentives for R&D, plus strategies to cap the rise of antimicrobial resistance on the table.